Payment overview · 2025
General Payments
$13.48
1 reported records · 1 companies
Healthcare provider profile · identity verified
Gilberto Cota, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEMON GROVE, CA · NPI 1184886186
Verified facts
What the public records show
CMS Open Payments records show Gilberto Cota, MD received $13.48 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.48 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.48 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 436 | 107 |
| Metformin Hcl | Metformin Hcl | 415 | 112 |
| Losartan Potassium | Losartan Potassium | 403 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 87 |
| Lisinopril | Lisinopril | 268 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 62 |
| Simvastatin | Simvastatin | 225 | 55 |
| Carvedilol | Carvedilol | 197 | 48 |
| Montelukast Sodium | Montelukast Sodium | 185 | 41 |
| Gabapentin | Gabapentin | 182 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 44 |
| Ozempic | Semaglutide | 168 | 26 |
| Buspirone Hcl | Buspirone Hcl | 167 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 162 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 33 |
| Meloxicam | Meloxicam | 141 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 29 |
| Furosemide | Furosemide | 138 | 38 |
| Glimepiride | Glimepiride | 138 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 33 |
| Ibuprofen | Ibuprofen | 128 | 45 |
| Allopurinol | Allopurinol | 111 | 29 |
| Januvia | Sitagliptin Phosphate | 107 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 28 |
| Alendronate Sodium | Alendronate Sodium | 98 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 96 | 28 |
| Entresto | Sacubitril/Valsartan | 93 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 26 |
| Trazodone Hcl | Trazodone Hcl | 89 | 15 |
| Clonazepam | Clonazepam | 77 | 23 |
| Nifedipine Er | Nifedipine | 77 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 20 |
| Memantine Hcl | Memantine Hcl | 74 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 19 |
| Baclofen | Baclofen | 66 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 28 |
| Jardiance | Empagliflozin | 64 | 15 |
| Sertraline Hcl | Sertraline Hcl | 64 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 63 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 21 |
| Tradjenta | Linagliptin | 59 | 12 |
| Finasteride | Finasteride | 56 | 12 |
| Azithromycin | Azithromycin | 55 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 20 |
| Meclizine Hcl | Meclizine Hcl | 53 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 13 |
| Eliquis | Apixaban | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 36 |
| Famotidine | Famotidine | 41 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Naproxen | Naproxen | 37 | 12 |
| Pregabalin | Pregabalin | 37 | 11 |
| Sucralfate | Sucralfate | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 11 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 14 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Gemtesa | Vibegron | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pulmicort Flexhaler | Budesonide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.48 · 1 records | AstraZeneca Pharmaceuticals LP | TEZSPIRE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error